Human immunodeficiency virus type 1 (HIV-1), the causative agent of acquired immunodeficiency syndrome, encodes four accessory genes, one of which is viral protein U (Vpu). Recently, the study of Vpu has been of great interest. For instance, various cellular proteins are degraded (e.g. CD4) and down-modulated (e.g. tetherin) by Vpu. Vpu also antagonizes the function of tetherin and inhibits NF-κB. Moreover, Vpu is a viroporin forming ion channels and may represent a promising target for anti-HIV-1 drugs. In this review, we summarize the domains/residues that are responsible for Vpu’s functions, describe the current understanding of the role of Vpu in HIV-1-infected cells, and review the effect of Vpu on HIV-1 in replication and pathogenesis. Future investigations that simultaneously assess a combination of Vpu functions are required to clearly delineate the most important functions for viral replication.
Impact statement
Viral protein U (Vpu) is a unique protein encoded by human immunodeficiency virus type 1 (HIV-1) and related lentiviruses, playing multiple roles in viral replication and pathogenesis. In this review, we briefly summarize the most up-to-date knowledge of HIV-1 Vpu.
Barre-SinoussiFChermannJCReyFNugeyreMTChamaretSGruestJDauguetCAxler-BlinCVezinet-BrunFRouziouxCRozenbaumWMontagnierL. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science1983; 220: 868–71.
2.
GalloRCSarinPSGelmannEPRobert-GuroffMRichardsonEKalyanaramanVSMannDSidhuGDStahlREZolla-PaznerSLeibowitchJPopovicM. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science1983; 220: 865–7.
3.
StrebelKKlimkaitTMartinMA. A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science1988; 241: 1221–3.
4.
CohenEATerwilligerEFSodroskiJGHaseltineWA. Identification of a protein encoded by the vpu gene of HIV-1. Nature1988; 334: 532–4.
5.
GiffordRJ. Viral evolution in deep time: lentiviruses and mammals. Trends Genet2012; 28: 89–100.
6.
GrovesCPOrder primates. In: WilsonDEReederDM (eds). Mammal species of the world: a taxonomic and geographic reference, 3rd ed. Baltimore: Johns Hopkins University Press, 2005, pp. 111–84.
7.
KirchhoffF. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe2010; 8: 55–67.
FreedEOMartinMAHIVs and their replication. In: KnipeDMHowleyPM (eds). Fields virology, 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2007, pp. 2107–85.
10.
SchwartzSFelberBKFenyoEMPavlakisGN. Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs. J Virol1990; 64: 5448–56.
11.
OchsenbauerCEdmondsTGDingHKeeleBFDeckerJSalazarMGSalazar-GonzalezJFShattockRHaynesBFShawGMHahnBHKappesJC. Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol2012; 86: 2715–28.
12.
Salazar-GonzalezJFSalazarMGKeeleBFLearnGHGiorgiEELiHDeckerJMWangSBaalwaJKrausMHParrishNFShawKSGuffeyMBBarKJDavisKLOchsenbauer-JamborCKappesJCSaagMSCohenMSMulengaJDerdeynCAAllenSHunterEMarkowitzMHraberPPerelsonASBhattacharyaTHaynesBFKorberBTHahnBHShawGM. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med2009; 206: 1273–89.
13.
KrappCHotterDGawanbachtAMcLarenPJKlugeSFSturzelCMMackKReithEEngelhartSCiuffiAHornungVSauterDTelentiAKirchhoffF. Guanylate binding protein (GBP) 5 is an interferon-inducible inhibitor of HIV-1 infectivity. Cell Host Microbe2016; 19: 504–14.
14.
PurcellDFMartinMA. Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J Virol1993; 67: 6365–78.
15.
OcwiejaKESherrill-MixSMukherjeeRCusters-AllenRDavidPBrownMWangSLinkDROlsonJTraversKSchadtEBushmanFD. Dynamic regulation of HIV-1 mRNA populations analyzed by single-molecule enrichment and long-read sequencing. Nucleic Acids Res2012; 40: 10345–55.
16.
KozakM. How do eucaryotic ribosomes select initiation regions in messenger RNA?Cell1978; 15: 1109–23.
17.
KozakM. The scanning model for translation: an update. J Cell Biol1989; 108: 229–41.
18.
KrummheuerJJohnsonATHauberIKammlerSAndersonJLHauberJPurcellDFSchaalH. A minimal uORF within the HIV-1 vpu leader allows efficient translation initiation at the downstream env AUG. Virology2007; 363: 261–71.
19.
DalgleishAGBeverleyPCClaphamPRCrawfordDHGreavesMFWeissRA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature1984; 312: 763–7.
20.
KlatzmannDChampagneEChamaretSGruestJGuetardDHercendTGluckmanJCMontagnierL. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature1984; 312: 767–8.
21.
McDougalJSMaddonPJOrloffGClaphamPRDalgleishAGJamalSWeissRAAxelRA. Role of CD4 in the penetration of cells by HIV. Adv Exp Med Biol1991; 300: 145–54; discussion 55–8.
22.
LevesqueKFinziABinetteJCohenEA. Role of CD4 receptor down-regulation during HIV-1 infection. Curr HIV Res2004; 2: 51–9.
23.
WilleyRLMaldarelliFMartinMAStrebelK. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol1992; 66: 7193–200.
24.
BourSSchubertUStrebelK. The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4: implications for the mechanism of degradation. J Virol1995; 69: 1510–20.
25.
MargottinFBourSPDurandHSeligLBenichouSRichardVThomasDStrebelKBenarousR. A novel human WD protein, h-βTrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell1998; 1: 565–74.
26.
BinetteJDubeMMercierJHalawaniDLatterichMCohenEA. Requirements for the selective degradation of CD4 receptor molecules by the human immunodeficiency virus type 1 Vpu protein in the endoplasmic reticulum. Retrovirology2007; 4: 75–75.
27.
SchubertUAntonLCBacikICoxJHBourSBenninkJROrlowskiMStrebelKYewdellJW. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J Virol1998; 72: 2280–8.
28.
LeonSHaguenauer-TsapisR. Ubiquitin ligase adaptors: regulators of ubiquitylation and endocytosis of plasma membrane proteins. Exp Cell Res2009; 315: 1574–83.
29.
MagadanJGPerez-VictoriaFJSougratRYeYStrebelKBonifacinoJS. Multilayered mechanism of CD4 downregulation by HIV-1 Vpu involving distinct ER retention and ERAD targeting steps. PLoS Pathog2010; 6: e1000869–e1000869.
30.
MeusserBSommerT. Vpu-mediated degradation of CD4 reconstituted in yeast reveals mechanistic differences to cellular ER-associated protein degradation. Mol Cell2004; 14: 247–58.
31.
JaroschETaxisCVolkweinCBordalloJFinleyDWolfDHSommerT. Protein dislocation from the ER requires polyubiquitination and the AAA-ATPase Cdc48. Nat Cell Biol2002; 4: 134–9.
32.
RabinovichEKeremAFrohlichKUDiamantNBar-NunS. AAA-ATPase p97/Cdc48p, a cytosolic chaperone required for endoplasmic reticulum-associated protein degradation. Mol Cell Biol2002; 22: 626–34.
33.
YeYMeyerHHRapoportTA. The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol. Nature2001; 414: 652–6.
34.
YeYMeyerHHRapoportTA. Function of the p97-Ufd1-Npl4 complex in retrotranslocation from the ER to the cytosol: dual recognition of nonubiquitinated polypeptide segments and polyubiquitin chains. J Cell Biol2003; 162: 71–84.
35.
VarthakaviVSmithRMBourSPStrebelKSpearmanP. Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc Natl Acad Sci USA2003; 100: 15154–9.
36.
NeilSJSandrinVSundquistWIBieniaszPD. An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe2007; 2: 193–203.
37.
NeilSJZangTBieniaszPD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature2008; 451: 425–30.
38.
Van DammeNGoffDKatsuraCJorgensonRLMitchellRJohnsonMCStephensEBGuatelliJ. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe2008; 3: 245–52.
39.
SauterD. Counteraction of the multifunctional restriction factor tetherin. Front Microbiol2014; 5: 163–163.
40.
ViganRNeilSJ. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. J Virol2010; 84: 12958–70.
41.
DouglasJLViswanathanKMcCarrollMNGustinJKFruhKMosesAV. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a βTrCP-dependent mechanism. J Virol2009; 83: 7931–47.
42.
GoffinetCAllespachIHomannSTervoHMHabermannARuppDOberbremerLKernCTibroniNWelschSKrijnse-LockerJBantingGKrausslichHGFacklerOTKepplerOT. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe2009; 5: 285–97.
43.
MitchellRSKatsuraCSkaskoMAFitzpatrickKLauDRuizAStephensEBMargottin-GoguetFBenarousRGuatelliJC. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via β-TrCP and endo-lysosomal trafficking. PLoS Pathog2009; 5: e1000450–e1000450.
44.
KueckTFosterTLWeineltJSumnerJCPickeringSNeilSJ. Serine phosphorylation of HIV-1 Vpu and its binding to tetherin regulates interaction with clathrin adaptors. PLoS Pathog2015; 11: e1005141–e1005141.
45.
SauterDSchindlerMSpechtALandfordWNMunchJKimKAVottelerJSchubertUBibollet-RucheFKeeleBFTakehisaJOgandoYOchsenbauerCKappesJCAyoubaAPeetersMLearnGHShawGSharpPMBieniaszPHahnBHHatziioannouTKirchhoffF. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe2009; 6: 409–21.
46.
SauterDHueSPetitSJPlantierJCTowersGJKirchhoffFGuptaRK. HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef. Retrovirology2011; 8: 103–103.
47.
ViganRNeilSJ. Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin. J Virol2011; 85: 9737–48.
48.
YangSJLopezLAExlineCMHaworthKGCannonPM. Lack of adaptation to human tetherin in HIV-1 group O and P. Retrovirology2011; 8: 78–78.
49.
SauterDUnterwegerDVoglMUsmaniSMHeigeleAKlugeSFHermkesEMollMBarkerEPeetersMLearnGHBibollet-RucheFFritzJVFacklerOTHahnBHKirchhoffF. Human tetherin exerts strong selection pressure on the HIV-1 group N Vpu protein. PLoS Pathog2012; 8: e1003093–e1003093.
BailesEGaoFBibollet-RucheFCourgnaudVPeetersMMarxPAHahnBHSharpPM. Hybrid origin of SIV in chimpanzees. Science2003; 300: 1713–1713.
52.
ZhangFWilsonSJLandfordWCVirgenBGregoryDJohnsonMCMunchJKirchhoffFBieniaszPDHatziioannouT. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe2009; 6: 54–67.
53.
JiaBSerra-MorenoRNeidermyerWRahmbergAMackeyJFofanaIBJohnsonWEWestmorelandSEvansDT. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog2009; 5: e1000429–e1000429.
54.
KobayashiTTakeuchiJSRenFMatsudaKSatoKKimuraYMisawaNYoshikawaRNakanoYYamadaETanakaHHirschVMKoyanagiY. Characterization of red-capped mangabey tetherin: implication for the co-evolution of primates and their lentiviruses. Sci Rep2014; 4: 5529–5529.
55.
KlugeSFMackKIyerSSPujolFMHeigeleALearnGHUsmaniSMSauterDJoasSHotterDBibollet-RucheFPlenderleithLJPeetersMGeyerMSharpPMFacklerOTHahnBHKirchhoffF. Nef proteins of epidemic HIV-1 group O strains antagonize human tetherin. Cell Host Microbe2014; 16: 639–50.
56.
BottinoCFalcoMParoliniSMarcenaroEAugugliaroRSivoriSLandiEBiassoniRNotarangeloLDMorettaLMorettaA. NTB-A [correction of GNTB-A], a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease. J Exp Med2001; 194: 235–46.
57.
FlaigRMStarkSWatzlC. Cutting edge: NTB-A activates NK cells via homophilic interaction. J Immunol2004; 172: 6524–7.
58.
WardJBonaparteMSacksJGutermanJFogliMMavilioDBarkerE. HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts. Blood2007; 110: 1207–14.
59.
FogliMMavilioDBrunettaEVarchettaSAtaKRobyGKovacsCFollmannDPendeDWardJBarkerEMarcenaroEMorettaAFauciAS. Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals. PLoS Pathog2008; 4: e1000101–e1000101.
60.
ShahAHSowrirajanBDavisZBWardJPCampbellEMPlanellesVBarkerE. Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu. Cell Host Microbe2010; 8: 397–409.
61.
BolduanSHubelPReifTLodermeyerVHohneKFritzJVSauterDKirchhoffFFacklerOTSchindlerMSchubertU. HIV-1 Vpu affects the anterograde transport and the glycosylation pattern of NTB-A. Virology2013; 440: 190–203.
62.
DouglasJLGustinJKViswanathanKMansouriMMosesAVFruhK. The great escape: viral strategies to counter BST-2/tetherin. PLoS Pathog2010; 6: e1000913–e1000913.
63.
MathesonNJSumnerJWalsKRapiteanuRWeekesMPViganRWeineltJSchindlerMAntrobusRCostaASFrezzaCClishCBNeilSJLehnerPJ. Cell surface proteomic map of HIV infection reveals antagonism of amino acid metabolism by Vpu and Nef. Cell Host Microbe2015; 18: 409–23.
64.
MackenzieBEricksonJD. Sodium-coupled neutral amino acid (System N/A) transporters of the SLC38 gene family. Pflugers Arch2004; 447: 784–95.
65.
GuSRoderickHLCamachoPJiangJX. Characterization of an N-system amino acid transporter expressed in retina and its involvement in glutamine transport. J Biol Chem2001; 276: 24137–44.
66.
VaroquiHZhuHYaoDMingHEricksonJD. Cloning and functional identification of a neuronal glutamine transporter. J Biol Chem2000; 275: 4049–54.
67.
ChakrabortySRahmanTChakravortyR. Characterization of the protective HIV-1 CTL Epitopes and the corresponding HLA class I alleles: a step towards designing CTL based HIV-1 vaccine. Adv Virol2014; 2014: 321974–321974.
68.
CarringtonMO’BrienSJ. The influence of HLA genotype on AIDS. Annu Rev Med2003; 54: 535–51.
69.
MarshJW. The numerous effector functions of Nef. Arch Biochem Biophys1999; 365: 192–8.
MollMAnderssonSKSmed-SorensenASandbergJK. Inhibition of lipid antigen presentation in dendritic cells by HIV-1 Vpu interference with CD1d recycling from endosomal compartments. Blood2010; 116: 1876–84.
72.
ZajoncDM. The CD1 family: serving lipid antigens to T cells since the Mesozoic era. Immunogenetics2016; 68: 561–76.
73.
de JongA. Activation of human T cells by CD1 and self-lipids. Immunol Rev2015; 267: 16–29.
74.
BachleSMSauterDSibitzSSandbergJKKirchhoffFMollM. Involvement of a C-terminal motif in the interference of primate lentiviral Vpu proteins with CD1d-mediated antigen presentation. Sci Rep2015; 5: 9675–9675.
75.
HallerCMullerBFritzJVLamas-MuruaMStolpBPujolFMKepplerOTFacklerOT. HIV-1 Nef and Vpu are functionally redundant broad-spectrum modulators of cell surface receptors, including tetraspanins. J Virol2014; 88: 14241–57.
76.
LambeleMKoppensteinerHSymeonidesMRoyNHChanJSchindlerMThaliM. Vpu is the main determinant for tetraspanin downregulation in HIV-1-infected cells. J Virol2015; 89: 3247–55.
77.
SatoKAokiJMisawaNDaikokuESanoKTanakaYKoyanagiY. Modulation of human immunodeficiency virus type 1 infectivity through incorporation of tetraspanin proteins. J Virol2008; 82: 1021–33.
78.
KrementsovDNWengJLambeleMRoyNHThaliM. Tetraspanins regulate cell-to-cell transmission of HIV-1. Retrovirology2009; 6: 64–64.
79.
WengJKrementsovDNKhuranaSRoyNHThaliM. Formation of syncytia is repressed by tetraspanins in human immunodeficiency virus type 1-producing cells. J Virol2009; 83: 7467–74.
80.
RamirezPWFamigliettiMSowrirajanBDePaula-SilvaABRodeschCBarkerEBosqueAPlanellesV. Downmodulation of CCR7 by HIV-1 Vpu results in impaired migration and chemotactic signaling within CD4+ T cells. Cell Rep2014; 7: 2019–30.
81.
VassenaLGiulianiEKoppensteinerHBolduanSSchindlerMDoriaM. HIV-1 Nef and Vpu interfere with L-selectin (CD62L) cell surface expression to inhibit adhesion and signaling in infected CD4+ T lymphocytes. J Virol2015; 89: 5687–700.
82.
BolduanSReifTSchindlerMSchubertU. HIV-1 Vpu mediated downregulation of CD155 requires alanine residues 10, 14 and 18 of the transmembrane domain. Virology2014; 464–465: 375–84.
83.
ChanJKGreeneWC. Dynamic roles for NF-κB in HTLV-I and HIV-1 retroviral pathogenesis. Immunol Rev2012; 246: 286–310.
84.
GalaoRPLe TortorecAPickeringSKueckTNeilSJ. Innate sensing of HIV-1 assembly by tetherin induces NFκB-dependent proinflammatory responses. Cell Host Microbe2012; 12: 633–44.
85.
SauterDHotterDVan DriesscheBSturzelCMKlugeSFWildumSYuHBaumannBWirthTPlantierJCLeozMHahnBHVan LintCKirchhoffF. Differential regulation of NF-κB-mediated proviral and antiviral host gene expression by primate lentiviral Nef and Vpu proteins. Cell Rep2015; 10: 586–99.
86.
EwartGDSutherlandTGagePWCoxGB. The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. J Virol1996; 70: 7108–15.
87.
MaldarelliFChenMYWilleyRLStrebelK. Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein. J Virol1993; 67: 5056–61.
88.
GonzalezME. Vpu protein: the viroporin encoded by HIV-1. Viruses2015; 7: 4352–68.
89.
HerreroLMonroyNGonzalezME. HIV-1 Vpu protein mediates the transport of potassium in Saccharomyces cerevisiae. Biochemistry2013; 52: 171–7.
90.
HuangDTChiNChenSCLeeTYHsuK. Background K(2P) channels KCNK3/9/15 limit the budding of cell membrane-derived vesicles. Cell Biochem Biophys2011; 61: 585–94.
91.
HsuKHanJShinlapawittayatornKDeschenesIMarbanE. Membrane potential depolarization as a triggering mechanism for Vpu-mediated HIV-1 release. Biophys J2010; 99: 1718–25.
92.
EwartGDNasrNNaifHCoxGBCunninghamALGagePW. Potential new anti-human immunodeficiency virus type 1 compounds depress virus replication in cultured human macrophages. Antimicrob Agents Chemother2004; 48: 2325–30.
93.
EwartGDMillsKCoxGBGagePW. Amiloride derivatives block ion channel activity and enhancement of virus-like particle budding caused by HIV-1 protein Vpu. Eur Biophys J2002; 31: 26–35.
94.
KhouryGEwartGLuscombeCMillerMWilkinsonJ. Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages. Antimicrob Agents Chemother2010; 54: 835–45.
95.
GazinaEVPetrouS. Viral targets of acylguanidines. Drug Discov Today2012; 17: 1039–43.
96.
MwimanziPTietjenIMillerSCShahidACobarrubiasKKinlochNNBarakiBRichardJFinziAFedidaDBrummeZLBrockmanMA. Novel acylguanidine-based inhibitor of HIV-1. J Virol2016; 90: 9495–508.
97.
BolduanSVottelerJLodermeyerVGreinerTKoppensteinerHSchindlerMThielGSchubertU. Ion channel activity of HIV-1 Vpu is dispensable for counteraction of CD317. Virology2011; 416: 75–85.
98.
MehnertTRouthAJudgePJLamYHFischerDWattsAFischerWB. Biophysical characterization of Vpu from HIV-1 suggests a channel-pore dualism. Proteins2008; 70: 1488–97.
99.
GreinerTBolduanSHertelBGrossCHamacherKSchubertUMoroniAThielG. Ion channel activity of Vpu proteins is conserved throughout evolution of HIV-1 and SIV. Viruses2016; 8: E325–E325.
100.
IchinoheTPangIKIwasakiA. Influenza virus activates inflammasomes via its intracellular M2 ion channel. Nat Immunol2010; 11: 404–10.
McLarenPJGawanbachtAPyndiahNKrappCHotterDKlugeSFGotzNHeilmannJMackKSauterDThompsonDPerreaudJRausellAMunozMCiuffiAKirchhoffFTelentiA. Identification of potential HIV restriction factors by combining evolutionary genomic signatures with functional analyses. Retrovirology2015; 12: 41–41.
PickeringSHueSKimEYReddySWolinskySMNeilSJ. Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals. PLoS Pathog2014; 10: e1003895–e1003895.
105.
RatnerLHaseltineWPatarcaRLivakKJStarcichBJosephsSFDoranERRafalskiJAWhitehornEABaumeisterKIvanoffLPettewaySRPearsonMLLautenbergerJAPapasTSGhrayebJChangNTGalloRCWong-StaalF. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature1985; 313: 277–84.
106.
RatnerLFisherAJagodzinskiLLMitsuyaHLiouRSGalloRCWong-StaalF. Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res Hum Retroviruses1987; 3: 57–69.
107.
AlizonMWain-HobsonSMontagnierLSonigoP. Genetic variability of the AIDS virus: nucleotide sequence analysis of two isolates from African patients. Cell1986; 46: 63–74.
108.
SrinivasanAAnandRYorkDRanganathanPFeorinoPSchochetmanGCurranJKalyanaramanVSLuciwPASanchez-PescadorR. Molecular characterization of human immunodeficiency virus from Zaire: nucleotide sequence analysis identifies conserved and variable domains in the envelope gene. Gene1987; 52: 71–82.
109.
GummuluruSKinseyCMEmermanM. An in vitro rapid-turnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus. J Virol2000; 74: 10882–91.
110.
JollyCBoothNJNeilSJ. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. J Virol2010; 84: 12185–99.
AldrovandiGMZackJA. Replication and pathogenicity of human immunodeficiency virus type 1 accessory gene mutants in SCID-hu mice. J Virol1996; 70: 1505–11.
113.
DaveVPHajjarFDiengMMHaddadECohenEA. Efficient BST2 antagonism by Vpu is critical for early HIV-1 dissemination in humanized mice. Retrovirology2013; 10: 128–128.
114.
SatoKMisawaNFukuharaMIwamiSAnDSItoMKoyanagiY. Vpu augments the initial burst phase of HIV-1 propagation and downregulates BST2 and CD4 in humanized mice. J Virol2012; 86: 5000–13.
